Meeting
2015 Gastrointestinal Cancers Symposium
A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonaïve advanced esophagogastric cancer (AEGC).
Authors
Markus Hermann Moehler
Johannes-Gutenberg University Mainz, Mainz, Germany
Markus Hermann Moehler , Volker Heinemann , Radka Obermannova , Eugen Kubala , Bohuslav Melichar , Rolf Mahlberg , Arndt Weinmann , Paul Scigalla , Marietta Tesarova , Petr Janda , Fabienne Biville-Hedouin , Wasat Mansoor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
2011-003471-11
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 140)
DOI
10.1200/jco.2015.33.3_suppl.140
Abstract #
140
Poster Bd #
C38
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 dose-finding trial of cabozantinib (cabo) and trifluridine/tipiracil (FDT/TPI) in metastatic colorectal carcinoma (mCRC).
First Author: Farshid Dayyani
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of FLOT as first-line treatment for advanced gastric cancer with/without severe peritoneal metastasis: Results of dose-finding part.
First Author: Kazuhiro Shiraishi
Poster
2019 Gastrointestinal Cancers Symposium
A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).
First Author: Hiroki Yukami
Poster
2016 Gastrointestinal Cancers Symposium
S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies.
First Author: Camilla Qvortrup